PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Liqmeds Worldwide Limited

USPTO PatentsView assignee record - 28 granted patents across 2 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Liqmeds ranks #10,988 of 49,997 tracked US assignees by granted-patent volume, with 28 patents across 2 technology areas.

#10,988
of 49,997 US assignees by volume
Top 15%
by Innovation Score (49.1/100)
20.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R10988 · Foreign Corporation #10,988 · 28 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-SMALL 28 grants
  • UPPER-Q #10,988/49,997
  • PHOTO-FINISH Leeo
  • CPC-NARROW A61K · 2 areas
  • INNOV-PAR 49.1/100
  • CLAIMS-DENSE 20.8 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2022–2025 · 4y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Leeo, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Liqmeds’s 49.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Liqmeds

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Liqmeds's Innovation Score is 49.1/100 (top 15% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Liqmeds?

Each dot is one of Liqmeds’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Liqmeds’s own 20.8 claims/patent is ABOVE the 15.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Liqmeds vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 27.92828.1 510152025 Granted patents (volume) Avg claims / patent Leeo, Inc. - 28, 15.11LeeoLevitation Sciences LLC - 28, 22.79Levitation Scienc…Leybold GmBH - 28, 15.11LeyboldLinamar Corporation - 28, 16.54LinamarMaersk Olie OG GAS A/S - 28, 21.07Maersk Olie OG GA…Makinarocks Co., Ltd. - 28, 13.75MakinarocksManitou BF - 28, 9.07Manitou BFMatrixed Reality Technology Co., Ltd. - 28, 13.71Matrixed Reality…Liqmeds Worldwide Limited - 28, 20.82Liqmeds Worldwide
Liqmeds vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Liqmeds's grants concentrate

Liqmeds Worldwide Limited is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2024 (9 grants) versus a trough of 4 in 2023. By volume, Liqmeds sits between Leeo, Inc. and Matrixed Reality Technology Co., Ltd..

Liqmeds's three-year grant acceleration

Liqmeds Worldwide Limited shows 19 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Liqmeds's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Liqmeds holds 28 patents at rank #10,988, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Liqmeds

By rank, the assignees closest to #10,988 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Liqmeds's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Liqmeds, neither rank-band nor same-CPC leaders (those blocks stay above). In A61K (Preparations FOR Medical), Liqmeds ranks #814 of 7,163 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (49 here).

SUN Pharmaceutical Industries Limited 49 Razor USA LLC 49 Alpha Assembly Solutions Inc. 49 Baxter Corporation Englewood 49

Liqmeds's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

49 Top 15% higher than 85% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

246810 2022202320242025 9
USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table
Liqmeds Worldwide Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2022 6 21.4%
2023 4 14.3%
2024 9 32.1%
2025partial year 9 32.1%

Which technologies does Liqmeds Worldwide Limited patent most?

Top 2 of 2 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Liqmeds Worldwide Limited's patent record in context - here's where to go next.

  • Liqmeds Worldwide Limited's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
  • Ranked #10,988 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Liqmeds Worldwide Limited against Leeo, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 49.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.